Multiples Alternate Asset Management

Multiples Alternate Asset Management is a Mumbai-based mid-market private equity firm that drives growth-stage transactions across Indian healthcare and pharmaceuticals. Check sizes of $25M and above and a stage focus on growth equity place the firm well above the venture range; this is a firm for founders running revenue-scale businesses contemplating significant equity raises, not for early-stage technology founders.

The firm’s natural fit is with Indian healthcare operators with substantial commercial scale, including pharmaceutical manufacturers, specialty hospital chains, diagnostics platforms, contract development and manufacturing organizations, and tech-enabled care delivery businesses with proven unit economics. The firm’s pattern is operational and financial rather than thematic; AI is not the lens. The right CEO profile is a seasoned operator with audited financials, a credible board, and a clear thesis on how growth capital accelerates a defined market position. Pre-revenue founders, early Series A teams, and software-only AI plays are not the right fit.

Geographically, Multiples is deeply embedded in the Indian growth-stage market and connected to global growth investors who participate in pre-IPO rounds in India. The firm’s advantage is operational expertise in Indian healthcare regulation, manufacturing, and distribution. For non-Indian operators, the strategic value is thin.

The right entry path is via an investment banker leading the round, an existing growth-stage co-investor, or a board member with senior Indian growth-stage relationships. Decks should lead with audited financial history, growth metrics, market position, and a specific use of capital tied to a discrete commercial milestone. Be prepared for multi-month diligence including site visits, regulatory reviews, and management background checks.

Caveats. Growth equity introduces governance complexity, including specific protective provisions, drag-along rights, and exit timing expectations; engage experienced PE-track counsel from the start. The firm’s healthcare-specific portfolio is concentrated in pharma and care delivery; if your business is a digital health software platform, look at Indian growth funds with stronger software DNA. Multi-month diligence and committee-driven decision-making mean timeline planning is essential. For Indian healthcare and pharma operators at growth scale, Multiples is a credible domestic PE partner; for venture-stage technology founders, this is the wrong door.